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MaOBJECTIVES The purpose of this study was to investigate the effects of mineralocorticoid receptor antagonists (MRAs)
on systolic blood pressure (SBP) and outcomes according to baseline SBP in patients with heart failure with reduced
ejection fraction (HFrEF).
BACKGROUND MRAs are greatly underused inpatientswithHFrEF, often because of fear of adverse events. Concern about
hypotension has been raised by the demonstration that MRAs are particularly effective treatment for resistant hypertension.
METHODS The effect of MRA therapy was studied in 4,396 patients with HFrEF randomized in the RALES (Randomized
Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in
Heart Failure) trials.
RESULTS Mean SBP change from baseline to 6 months was þ1.4  18.1 mm Hg in the placebo group and 1.2 
17.9 mm Hg in the MRA group. The between-treatment difference was 2.6 mm Hg (95% confidence interval [CI]: 1.5 to
3.6; p < 0.001). All outcomes were reduced by MRA therapy overall, with consistent effects across SBP categories
(e.g., all-cause mortality, overall hazard ratio [HR] of 0.72; 95% CI: 0.64 to 0.82; p < 0.001; SBP #105 mm Hg; HR:
0.72; 95% CI: 0.56 to 0.94; SBP >105 to #115 mm Hg; HR: 0.78; 95% CI: 0.60 to 1.02; SBP >115 to #125 mm Hg; HR:
0.71; 95% CI: 0.53 to 0.94; SBP >125 to #135 mm Hg; HR: 0.79; 95% CI: 0.57 to 1.10; and SBP > 135 mm Hg; HR: 0.67;
95% CI: 0.50 to 0.90; p for interaction ¼ 0.95). Hypotension was infrequent and not more common with MRA therapy
than with placebo, overall (4.6% vs. 3.9%; p ¼ 0.25) or in any SBP category.
CONCLUSIONS MRA treatment had little effect on SBP in patientswithHFrEF, and the clinical benefitswere notmodified
by baseline SBP. MRA treatment infrequently caused hypotension, even when the baseline SBP was low. The treatment
discontinuation rates between MRA and placebo therapy were similar. Low SBP is not a reason to withhold MRA therapy in
patients with HFrEF. (J Am Coll Cardiol HF 2020;8:188–98) © 2020 by the American College of Cardiology Foundation.N 2213-1779/$36.00 https://doi.org/10.1016/j.jchf.2019.09.011
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189AB BR E V I A T I O N S
AND ACRONYM S
ACE = angiotensin converting-
enzyme
ARBs = angiotensin receptor
blockers
BP = blood pressure
eGFR = estimated glomerular
filtration rate
HFrEF = heart failure with
reduced ejection fraction
LVEF = left ventricular
ejection fraction
MRAs = mineralocorticoid
receptor antagonists
NYHA = New York heart
association
SBP = systolic blood pressureA lthough mineralocorticoid receptor antago-nist (MRA) therapy has been shown in ran-domized trials to reduce mortality in
patients with heart failure and reduced ejection frac-
tion (HFrEF), MRA therapy is greatly underused in
everyday practice (1, 2). Despite the evidence from
clinical trials and a Class I, Level of Evidence: A
recommendation in guidelines, registry data from
different regions of the world consistently show lower
use of MRA drugs than of angiotensin-converting
enzyme (ACE) inhibitors/angiotensin receptor
blockers (ARBs), or beta-blockers (3, 4). Hyperkalemia
is a well-recognized concern, leading to underpre-
scription of MRA drugs, but physicians also report an
unwillingness to prescribe these medications in pa-
tients with low blood pressure (5). The findings of
the recent PATHWAY-2 (Prevention And Treatment
of Hypertension With Algorithm based therapY) trial
seem to have led to the perception that MRAs are
powerful antihypertensive agents and amplified the
concern about hypotension in patients with HFrEF
(6). In PATHWAY-2, spironolactone therapy started
at 25 mg daily and force-titrated to 50 mg reduced
home systolic blood pressure (SBP) by a mean of
8.70 mm Hg (95% confidence interval [CI]: 9.72
to 7.69; p < 0.0001) compared with placebo and
was more effective than alternative fourth-line drugs
(bisoprolol or doxazosin) in patients with resistant hy-
pertension already treated with an ACE inhibitor/ARB,
a calcium channel blocker, and a thiazide or thiazide-
like diuretic.
To determine whether physicians should be con-
cerned about MRA-induced hypotension in patients
with HFrEF, this study analyzed the effect of MRA
therapy on blood pressure and outcomes, according
to baseline blood pressure in the 2 major randomized
placebo-controlled trials using drugs in this class
(spironolactone and eplerenone) in patients with
HFrEF.
METHODS
DETAILS OF TRIALS INCLUDED. The design, baseline
findings, and primary results of the 2 trials have
been reported previously in detail (1,2,7,8). Partici-
pants in each trial provided written informed
consent. Briefly, the RALES (Randomized Aldactone
Evaluation Study) was an event-driven, double-blind,
placebo-controlled mortality trial. Patients with
New York Heart Association (NYHA) functional
classes III-IV heart failure with a ventricular ejection
fraction (LVEF) of #35% were randomly assigned
to receive placebo or spironolactone therapy.
The starting dosage of the study drug was 25 mgof spironolactone once daily or matching
placebo. After 8 weeks, the dosage could be
increased to 50 mg daily if the patient still
had symptoms of heart failure but did not
have hyperkalemia.
The EMPHASIS-HF (Eplerenone in Mild
Patients Hospitalization and Survival Study in
Heart Failure) trial was an event-driven,
double-blind, placebo-controlled trial with a
composite morbidity-mortality outcome (car-
diovascular death or heart failure hospitali-
zation). Patients with NYHA functional class II
heart failure with an LVEF of #35% were
randomly assigned to placebo or eplerenone
therapy. The starting dosage for the study
drug was eplerenone 25 mg once daily or
matching placebo. After 4 weeks, the dosage
was increased to 50 mg once daily, unless
there was hyperkalemia (or another intolerance).
Importantly, neither trial had a lower blood pres-
sure exclusion criterion. The median follow-up in
RALES was 24 months and 21 months in EMPHASIS-
HF. In order to have an adequate number of pa-
tients (and events) in each baseline blood pressure
category of interest (see below) and to cover the full
spectrum of symptom severity (NYHA functional class
II to IV), the RALES and EMPHASIS-HF databases
were merged for analyses.
BASELINE BLOOD PRESSURE CATEGORIES AND
SERIAL BLOOD PRESSURE ASSESSMENTS. Patients
were divided into 5 baseline SBP categories: #105,
>105 to #115, >115 to #125, >125 to #135, and
>135 mm Hg, to ensure equally sized groups across
the spectrum of blood pressure values. In RALES, SBP
was measured at 1, 2, 3, 6, and 9 months and at 1, 5,
and 9 months in EMPHASIS-HF. For the purpose of
this analysis, the 5- and 6-month measurements were
considered to have occurred at 6 months.
STUDY OUTCOMES. The primary outcome used in
this analysis was the composite of cardiovascular
death or heart failure hospitalization. The compo-
nents of this composite and all-cause death were
also examined. Furthermore, we analyzed the occur-
rence of investigator-reported hypotension, a
decrease in SBP $30 mm Hg at the 6-month mea-
surement, decrease of SBP <85 mm Hg at the 1-
month, 6-month and both measurements, elevation
of serum potassium (>5.5 mmol/l and >6.0 mmol/l),
elevation of serum creatinine ($2.5 mg/dl and
$3.0 mg/dl) and the rate of permanent study drug
discontinuation for any reason other than death
during the study follow-up.
TABLE 1 Baseline Characteristics of Patients, Overall, and in Each SBP Category
SBP (mm Hg)
p Value
Overall
(N ¼ 4,396)
#105
(n ¼ 702)
>105 to #115
(n ¼ 870)
>115 to #125
(n ¼ 960)
>125 to #135
(n ¼ 823)
>135
(n ¼ 1,041)
SBP, mm Hg 123.4  18.2 97.6  5.8 110.8  2.2 120.8  2.2 130.6  2.1 148.0  11.4 <0.001
DBP, mm Hg 74.6  10.8 64.0  8.0 69.6  7.9 74.4  7.9 77.9  7.8 83.5  10.3 <0.001
Age, yrs 67.3  9.6 65.5  10.6 66.2  10.5 67.5  9.3 68.2  8.7 68.6  8.8 <0.001
Females 1,056 (24.0) 163 (23.2) 190 (21.8) 226 (23.5) 180 (21.9) 297 (28.5) 0.003
Race <0.001
White 3,705 (84.3) 553 (78.8) 716 (82.3) 831 (86.6) 718 (87.2) 887 (85.2)
Black 187 (4.3) 46 (6.6) 43 (4.9) 29 (3.0) 20 (2.4) 49 (4.7)
Asian 347 (7.9) 68 (9.7) 76 (8.7) 61 (6.4) 60 (7.3) 82 (7.9)
Other 157 (3.6) 35 (5.0) 35 (4.0) 39 (4.1) 25 (3.0) 23 (2.2)
NYHA functional class <0.001
I 1 (<0.1) 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0)
II 2,741 (62.4) 373 (53.1) 517 (59.4) 631 (65.7) 566 (68.8) 654 (62.8)
III 1,171 (26.6) 205 (29.2) 249 (28.6) 233 (24.3) 187 (22.7) 297 (28.5)
IV 483 (11.0) 124 (17.7) 104 (12.0) 95 (9.9) 70 (8.5) 90 (8.6)
Ischemic cause 2,792 (63.6) 406 (57.9) 536 (61.6) 627 (65.3) 552 (67.2) 671 (64.6) 0.001
Hypertension 2,208 (50.2) 201 (28.6) 358 (41.1) 497 (51.8) 489 (59.4) 663 (63.7) <0.001
Diabetes 1,227 (27.9) 158 (22.5) 218 (25.1) 243 (25.4) 266 (32.3) 342 (32.9) <0.001
Previous angina 1,297 (29.5) 145 (20.7) 225 (25.9) 300 (31.3) 294 (35.7) 333 (32.0) <0.001
Previous MI 1,852 (42.1) 275 (39.2) 364 (41.8) 433 (45.2) 365 (44.3) 415 (39.9) 0.039
Heart rate, beats/min 75.2  13.9 76.4  14.0 75.4  14.1 74.4  13.6 74.9  13.2 75.2  14.3 0.058
LVEF, % 25.8  5.6 24.2  6.5 25.4  5.7 25.9  5.3 26.4  5.2 26.8  5.0 <0.001
Potassium, mg/dl 4.28  0.44 4.24  0.44 4.26  0.43 4.30  0.45 4.30  0.44 4.29  0.42 0.019
Creatinine, mg/dl 1.18  0.33 1.24  0.34 1.18  0.34 1.18  0.33 1.16  0.31 1.16  0.33 <0.001
eGFR <60 ml/min/1.73 m2 1,699 (38.7) 316 (45.1) 332 (38.2) 382 (39.8) 282 (34.3) 387 (37.2) <0.001
Diuretics 3,826 (87.3) 629 (89.6) 765 (88.2) 843 (88.0) 697 (85.2) 892 (86.1) 0.06
ACE inhibitor or ARB 4,144 (94.6) 655 (93.3) 816 (94.1) 914 (95.4) 781 (95.5) 978 (94.4) 0.27
Beta-blockers 2,545 (58.1) 350 (49.9) 492 (56.7) 576 (60.1) 530 (64.8) 597 (57.6) <0.001
Digoxin 1,954 (44.6) 381 (54.3) 413 (47.6) 411 (42.9) 325 (39.7) 424 (40.9) <0.001
Values are mean  SD or n (%). The p values in bold indicate statistical significance.
ACE ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular filtration rate; MI ¼myocardial infarction; NYHA ¼ New
York Heart Association; LVEF ¼ left ventricular ejection fraction; SBP ¼ systolic blood pressure.
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190STATISTICAL ANALYSIS. Summary statistics for
baseline characteristics (including background treat-
ment) are provided for each SBP category (Table 1).
Continuous variables are shown as mean  SD and
categorical variables as frequencies and proportions.
Baseline variables, the occurrence of permanent
study drug discontinuation, and adverse effects were
compared across SBP categories by using ANOVA for
continuous variables and chi-square tests for cate-
gorical variables. The outcomes of interest across SBP
categories were illustrated using Kaplan-Meier anal-
ysis. Cox proportional hazards models were used to
estimate the hazard ratio for the effect of MRA
treatment in each SBP category and to calculate the p
value for the interaction between SBP category and
effect of treatment. The Cox regression models
included baseline age, sex, race, NYHA functional
class, cause by ischemia, history of hypertension,
diabetes, history of angina, history of myocardialinfarction, heart rate, LVEF, serum potassium and
serum creatinine concentrations, estimated glomer-
ular filtration rate category (60 ml/min/1.73 m2),
baseline use of beta blockers, and digoxin. Restricted
cubic spline analysis was used to examine the effect
of treatment according to baseline SBP modeled as a
continuous variable. The interaction between SBP as
a continuous variable and treatment, on the occur-
rence of the composite outcome, its components, and
all-cause death, was tested using an adjusted Cox
regression model. The interaction between SBP cate-
gory and treatment with reference to the occurrence
of adverse events and withdrawal from study drug
was tested using a logistic regression model with a
term for interaction between SBP category and
treatment. Changes in SBP were assessed by using a
repeated measures mixed model with the baseline
SBP as a covariate and treatment, time, and treatment
by time interactions as fixed effects. Sensitivity
FIGURE 1 Mean Change in SBP
Mean change in SBP from baseline to 1, 6, and 9 months in the placebo and in the MRA group in each baseline SBP category.
MRA ¼ mineralocorticoid receptor antagonist; SBP ¼ systolic blood pressure.
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191analysis was performed, analyzing baseline charac-
teristics, and rate of study outcome in the 2 trial
populations separately (complete analyses are
included in Online Tables S1 to S11, Online Figures S1
to S3). All statistical analyses were performed using
the Stata/SE version 15.1 software (Stata Corp, College
Station, Texas). All p values are 2-sided, and a p value
of <0.05 was considered significant.
RESULTS
Overall, 4,396 patients were included in the analysis,
of whom 2,214 were randomized to placebo and 2,182
to an MRA. There were 702 patients with a baseline
SBP of #105 mm Hg (a mean SBP of 97.6 TABLE 2 Change in Mean SBP From Baseline to 1 Month and to 6 Mont
Baseline SBP Category
Baseline to 1 Month
Placebo MRA
#105 mm Hg 8.9  15.1 6.1  13.5
>105 to #115 mm Hg 4.2  13.3 2.5  14.5
>115 to #125 mm Hg 0.9  13.1 0.2  14.5
>125 to #135 mm Hg 3.1  14.3 4.9  13.4
>135 mm Hg 10.0  16.6 11.9  17.7
Overall 0.5  15.9 2.4  16.3
Values are mean  SD changes in SBP.
MRA ¼ mineralocorticoid receptor antagonist; SBP ¼ systolic blood pressure.5.8 mm Hg); 870 patients with an SBP of >105
to #115 mm Hg (a mean SBP of 110.8  2.2 mm Hg);
960 patients with an SBP of >115 to #125 mm Hg (a
mean SBP of 120.8  2.2 mm Hg); 823 patients with an
SBP of >125 and #135 mm Hg (a mean SBP of 130.6 
2.1 mm Hg); and 1,041 patients with an SBP of
>135 mm Hg (mean SBP of 148  11.4 mm Hg).
BASELINE CHARACTERISTICS. The baseline charac-
teristics according to SBP category are shown in
Table 1. Patients with a lower SBP were younger, more
often male, and had worse NYHA functional class
status and lower median LVEF values. However,
participants with a lower SBP were less likely to have
a history of hypertension, coronary heart disease, orhs and Between-Treatment Differences in SBP, Overall, and in Each SBP Category
Baseline to 6 Months
Difference Placebo MRA Difference
2.8 12.3  16.2 9.6  15.1 2.8
1.7 6.6  16.4 4.8  15.9 1.7
0.7 2.9  15.0 2.4  15.8 0.4
1.8 0.9  16.4 3.7  14.0 2.9
1.8 9.3  18.6 13.0  18.0 3.6
1.9 1.4  18.1 1.2  17.9 2.6
TABLE 3 Effect of MRA Treatment on Clinical Outcomes Overall, and in Each SBP Category
Outcome
Number of Events (%)
Adjusted HR (95% CI),
p Value
p Value for
Interaction*Overall Placebo MRA
CV death or HF hospitalization 0.27
#105 mm Hg 312 (44.4) 176 (48.5) 136 (40.1) 0.74 (0.59–0.94), 0.012
>105 to #115 mm Hg 319 (36.7) 177 (41.1) 142 (32.2) 0.71 (0.56–0.90), 0.004
>115 to #125 mm Hg 293 (30.5) 177 (35.8) 116 (24.9) 0.62 (0.49–0.79), <0.001
>125 to #135 mm Hg 222 (27.0) 129 (30.6) 93 (23.2) 0.71 (0.54–0.94), 0.015
>135 mm Hg 275 (26.4) 169 (33.6) 106 (19.7) 0.52 (0.40–0.67), <0.001
Overall 1,421 (32.35) 828 (37.4) 593 (17.2) 0.66 (0.59–0.73), <0.001
Heart failure hospitalization 0.44
#105 mm Hg 192 (27.4) 113 (31.1) 79 (23.3) 0.66 (0.49–0.89), 0.006
>105 to #115 mm Hg 227 (26.1) 131 (30.4) 96 (21.9) 0.63 (0.48–0.83), 0.001
>115 to #125 mm Hg 189 (19.7) 110 (22.2) 79 (17.0) 0.69 (0.51–0.94), 0.017
>125 to #135 mm Hg 139 (16.9) 84 (19.9) 55 (13.7) 0.63 (0.44–0.90), 0.010
>135 mm Hg 185 (17.8) 115 (22.9) 70 (13.0) 0.50 (0.37–0.68), <0.001
Overall 932 (21.2) 553 (25.0) 379 (17.4) 0.63 (0.55–0.72), <0.001
Cardiovascular death 0.84
#105 mm Hg 216 (30.8) 119 (32.8) 97 (28.6) 0.79 (0.59–1.04), 0.092
>105 to #115 mm Hg 200 (23.0) 110 (25.5) 90 (20.5) 0.82 (0.62–1.11), 0.197
>115 to #125 mm Hg 178 (18.5) 107 (21.6) 71 (15.3) 0.67 (0.49–0.91), 0.010
>125 to #135 mm Hg 131 (15.9) 76 (18.0) 55 (13.7) 0.72 (0.50–1.03), 0.076
>135 mm Hg 145 (13.9) 87 (17.3) 58 (10.8) 0.61 (0.44–0.86), 0.005
Overall 870 (19.8) 499 (22.5) 371 (17.0) 0.71 (0.62–0.82), <0.001
All-cause death 0.95
#105 mm Hg 253 (36.0) 144 (39.7) 109 (32.2) 0.72 (0.56–0.94), 0.015
>105 to #115 mm Hg 243 (27.9) 135 (31.3) 108 (24.6) 0.78 (0.60–1.02), 0.073
>115 to #125 mm Hg 214 (22.3) 125 (25.3) 89 (19.1) 0.71 (0.53–0.94), 0.016
>125 to #135 mm Hg 154 (18.7) 86 (20.4) 68 (17.0) 0.79 (0.57–1.10), 0.163
>135 mm Hg 188 (18.1) 109 (21.7) 79 (14.7) 0.67 (0.50–0.90), 0.009
Overall 1,052 (23.9) 599 (27.1) 453 (20.8) 0.72 (0.64–0.82), <0.001
Values are n (%), unless otherwise noted. *The p values indicate interactions between SBP categories and treatment effects.
CI ¼ confidence interval; CV ¼ cardiovascular; HF ¼ heart failure; HR ¼ hazard ratio; MRA ¼ mineralocorticoid receptor antagonist; SBP ¼ systolic blood pressure.
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192diabetes. They had worse renal function and a slightly
lower potassium level than patients with a higher
SBP. Patients in the lowest SBP category were least
likely to be treated with a beta-blocker and more
likely to be treated with a diuretic drug and digoxin.
Use of an ACE inhibitor/ARB was similar across the
SBP categories.
CHANGE IN BLOOD PRESSURE. Overall, the mean
change in SBP from baseline to 1 month was 0.5 
15.9 mm Hg in the placebo group and 2.4 
16.3 mm Hg in the MRA group, resulting in a between-
treatment difference of 1.9 mm Hg (95% CI: 0.9 to 2.9;
p < 0.001). The corresponding values at 6 months
were þ1.4  18.1 mm Hg in the placebo group and 1.2
 17.9 mm Hg in the MRA group, giving a difference of
2.6 mm Hg (95% CI: 1.5 to 3.6; p < 0.001) and þ0.9 
17.8 mm Hg in the placebo group and 0.8 
18.0 mm Hg in the MRA group at 9 months; giving a
difference of 1.8 mm Hg (95% CI: 0.7 to
2.8; p ¼ 0.002).Figure 1 shows the mean change in SBP from
baseline during the first 9 months of treatment in
each of the SBP categories of interest. These changes
are also enumerated in Table 2. SBP increased in the
patients with the lowest starting SBP level and
decreased in those with a higher SBP at baseline.
Among patients in the lower SBP categories, SBP
increased less in MRA treated patients than in
placebo-treated patients. In patients in the higher
SBP categories, SBP decreased more with MRA ther-
apy than in those undergoing placebo treatment.
CLINICAL OUTCOMES. Examination of the placebo
group showed that the rates of all outcomes of in-
terest were higher in patients with a lower baseline
SBP (Table 3, Figure 2). Overall, compared with pla-
cebo, MRA therapy reduced the risk of the primary
composite outcome (cardiovascular death or heart
failure hospitalization), its components, and all-cause
death (Figures 2 and 3). The benefit of MRA therapy
was consistent across SBP categories, and there was
FIGURE 2 Cumulative Incidence of Cardiovascular Death or Hospitalization for Heart Failure According to Baseline SBP Categories
Kaplan-Meier curves for cardiovascular death or hospitalization for heart failure, overall, and in each SBP category. The p value is for interaction between baseline SBP
categories and treatment effect. The risk table below the graphs shows the number at risk of the event of interest. MRA denotes mineralocorticoid receptor antagonist.
Abbreviations as in Figure 1.
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193no evidence that baseline SBP modified the effect of
MRA therapy (the SBP-treatment interaction test
result was nonsignificant for each outcome of inter-
est) (Table 3, Figure 3). Similar findings were observed
examining pretreatment SBP as a continuous variable
(Online Figure S1).
ADVERSE EFFECTS AND STUDY DRUG DIS-
CONTINUATION. Overall, 186 patients (4.2%) expe-
rienced hypotension, 86 (3.9%) in the placebo group
and 100 (4.6%) in the MRA group (p ¼ 0.25) (Table 4).
The rate of hypotension in patients treated with pla-
cebo was highest in the lowest SBP group: 32 (8.8%) in
those with a SBP #105 mm Hg, 17 (3.9%) for SBP of 105
to 115 mm Hg, 16 (3.2%) for SBP of 115 to 125 mm Hg, 13
(3.1%) for SBP of 125 to 135 mm Hg, and 8 (1.6%) in
those with SBP > 135 mm Hg. The corresponding
numbers/proportions in MRA treated patients were 35
(10.3%), 18 (4.1%), 22 (4.7%), 9 (2.2%), and 16 (3.0%),
respectively. There was no interaction between SBP
category and the effect of treatment, with respect to
the occurrence of hypotension (Online Table S1).
Overall, 37 patients (0.8%) experienced a decrease
in SBP <85 mm Hg at the 1-month measurement, 16(0.7%) in the placebo group and 21 (1.0%) in the MRA
group (p ¼ 0.39). At the 6-month measurement, 29
patients (0.7%) showed a decrease in SBP <85 mm Hg,
12 (0.5%) in the placebo group and 17 (0.8%) in the
MRA group (p ¼ 0.33). Only 5 patients (0.1%) experi-
enced an SBP <85 mm Hg at both the 1-month and the
6-month assessments, 2 (0.1%) in the placebo group
and 3 (0.1%) in the MRA group (p ¼ 0.64).
Elevation of creatinine and potassium concentra-
tions was more common in the MRA than in the pla-
cebo group (Table 4), although the rate of these
adverse effects did not differ greatly across SBP cat-
egories (Online Table S1).
Overall, 876 patients (19.9%) permanently dis-
continued study treatment for reasons other than
death, 441 (19.9%) in the placebo group and 435
(19.9%) in the MRA group (p ¼ 0.99) (Table 4). The
overall number and rate of study drug discontinua-
tion in the placebo group was 85 (23.4%) in those with
an SBP of #105 mm Hg, 96 (22.3%) with an SBP of
>105 to #115 mm Hg, 86 (17.4%) with an SBP of >115
to #125 mm Hg, 82 (19.4%) with an SBP of >125
to #135 mm Hg, and 92 (18.3%) in those with an SBP of
>135 mm Hg. The corresponding numbers and
FIGURE 3 Adjusted HR for Clinical Outcomes According to SBP Categories
(A) Adjusted HR for cardiovascular death or hospitalization for heart failure, (B) hospitalization for heart failure, (C) cardiovascular death, and (D) all-cause death
overall, and in each SBP category. The p values are for interaction between baseline SBP categories and treatment effect. CI ¼ confidence interval, HR ¼ hazard ratio;
other abbreviations as in Figure 1.
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98 (22.3%), 88 (18.9%), 64 (16.0%), and 113 (21.0%),
respectively (Online Table S1). The rates of discon-
tinuation between the placebo and MRA groups did
not differ across SBP categories.
DISCUSSION
Neither RALES nor EMPHASIS-HF had a lower SBP
exclusion criterion, unlike most prior trials in pa-
tients with HFrEF (1,2). Accordingly, 702 of the 4,396
patients (16%) in the present study had an SBP
of #105 mm Hg. In keeping with most previous
studies, the present study found that patients with a
low SBP had worse outcomes, despite being younger
and having less comorbidity than patients with a
higher SBP; however, patients with lower SBP did
have more advanced NYHA functional class, more
renal impairment, and lower LVEF values (9–11).
The 2 major new findings of the present analyses
were that MRA treatment had little effect on bloodpressure in patients with HFrEF, in contrast to the
case in hypertension, and that the beneficial effect of
MRA therapy was not modified by baseline SBP
(Central Illustration).
Overall, the differences in SBP between the placebo
and the MRA therapy were small, namely 1.9 
0.5 mm Hg at 1 month and 2.6  0.6 mm Hg at
6 months (and did not differ between spironolactone
and eplerenone). It is instructive to compare this to
the reduction in SBP in PATHWAY-2 patients with
resistant hypertension (6). In PATHWAY-2, spi-
ronolactone was started at 25 mg daily for 6 weeks
and then force-titrated to 50 mg daily for a further
6 weeks (total treatment duration of 12 weeks). In
patients who received both doses of each tested drug,
the overall mean placebo-corrected reduction in
home SBP with spironolactone was 9.15 mm Hg (at
6 weeks it was 6.86 mm Hg and 11.4 mm Hg at
12 weeks). The corresponding mean overall placebo-
corrected reduction in clinic SBP was 9.92 mm Hg
(separate 6- and 12-week data were not reported). It is
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Serenelli, M. et al. J Am Coll Cardiol HF. 2020;8(3):188–98.
(A) Adjusted hazard ratios for all-cause death and (B) the mean change in SBP from baseline to 1, 6, and 9 months in each baseline SBP category. The
treatment effect and the small blood pressure-lowering effect observed are consistent across the baseline SBP categories. The p value is for interaction
between baseline SBP category and treatment effect. MRA ¼ mineralocorticoid receptor antagonist; SBP ¼ systolic blood pressure.
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195important to note that, because of this sequential
design, it was not possible to tell how much of the
incremental SBP reduction, if any, was due to the
increase in dose of spironolactone. Also, the average
dose of spironolactone attained was not reported in
PATHWAY-2. It is likely, however, that the proportion
of patients achieving the target dose of spi-
ronolactone in PATHWAY-2 was greater than the
proportion achieving the target dose of MRA in the 2
HFrEF trials, which had a similar forced-titration
design. In EMPHASIS-HF, only 60.2% of patients
assigned to eplerenone therapy were receiving 50 mg
daily at the end of the titration phase, and the meandaily dose of eplerenone was 39.1 mg (at 5 months).
Information for mean doses of spironolactone ach-
ieved during the first year of follow-up in RALES was
not available.
There are additional explanations, other than dose,
for the differences in SBP reduction between these
trials. One explanation is that PATHWAY-2 enrolled
patients with a higher mean SBP (148 mm Hg) than in
the present patients with HFrEF (123 mm Hg), and
generally, patients with higher starting SBP show a
greater reduction with treatment than those with a
lower baseline SBP (see below). However, the patients
in PATHWAY-2 had resistant hypertension, and the
TABLE 4 Adverse Effects of Interest and Permanent Study Drug Discontinuation
Event
Number of Adverse Effects (%)
Overall
(N ¼ 4,396)
Placebo
(n ¼ 2,214)
MRA
(n ¼ 2,182) p Value
Hypotension 186 (4.2) 86 (3.9) 100 (4.6) 0.25
SBP drop $30 mm Hg by 6 months 339 (7.7) 150 (6.8) 189 (8.7) 0.019
SBP <85 mm Hg at 1 month* 37 (0.8) 16 (0.7) 21 (1.0) 0.39
SBP <85 mm Hg at 6 months* 29 (0.7) 12 (0.5) 17 (0.8) 0.33
SBP <85 mm Hg at 1 and 6 months* 5 (0.1) 2 (0.1) 3 (0.1) 0.64
Creatinine $2.5 mg/dl 163 (3.7) 65 (2.9) 98 (4.5) 0.006
Creatinine $3.0 mg/dl 67 (1.5) 28 (1.3) 39 (1.8) 0.16
Potassium >5.5 mmol/l 419 (9.5) 132 (6.0) 287 (13.2) <0.001
Potassium >6.0 mmol/l 98 (2.2) 32 (1.4) 66 (3.0) <0.001
Discontinuation of study drug 876 (19.9) 441 (19.9) 435 (19.9) 0.99
Values are n (%). The p values in bold indicate statistical significance. *Patients with baseline SBP lower than
85 mm Hg were excluded from this analysis.
Abbreviations as in Tables 1 and 2.
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tested (bisoprolol and doxazosin) were approximately
one-half that obtained with spironolactone.
Alternatively, the PATHWAY-2 investigators pro-
posed that patients in their trial were especially
responsive to spironolactone because the major path-
ophysiological cause of resistant hypertension is so-
dium retention; however, this is also characteristic of
patients with HFrEF, yet in those patients, the reduc-
tion in SBP with MRA treatment was small. It has also
been suggested that spironolactone is particularly
effective in patients with resistant hypertension
because many have increased aldosterone secretion;
however, this is also true of patients with heart failure.
Although there may be no clear explanation for the
different SBP responses to MRA treatment in resistant
hypertension and HFrEF, differential SBP responses to
other therapies in hypertension and heart failure have
been reported. For example, in the second Cardiac
Insufficiency Bisoprolol Study (12), where patients
were titrated to a target dosage of bisoprolol, 10 mg
once daily, the placebo-corrected mean reduction in
SBP from baseline to 3 months was 1.37 (95% CI:
4.81 to 2.08) mm Hg (M Serenelli and J McMurray,
January 2020). This compares with a reduction in
home SBP at 3 months in the PATHWAY-2 study of 4.57
(95% CI: 5.60 to 3.54) mm Hg with the same beta-
blocker, titrated to the same daily dose. Consistent
with this was the reduction in SBP of 1.98 mm Hg at
6 weeks and 4.55 mmHg at 6 months with candesartan
titrated to a dosage of 32 mg daily in the
CHARM-Alternative (Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity-
Alternative) trial (13) (M Serenelli and J McMurray,
January 2020), compared to a reduction of 10.5 mm Hgafter 8 weeks with the dosing approach in patients
with hypertension (14). In other words, there is good
evidence that the SBP decrease in response to 3
different classes of drugs is different in HFrEF than in
hypertension. Although the explanation why is un-
certain, there is an important lesson here for health
care providers who may be concerned about giving
drugs considered to be “antihypertensives” to pa-
tients with HFrEF.
As in other HFrEF trials examining the effect of
different heart failure medications on SBP, patients in
RALES and EMPHASIS-HF with the lowest baseline
SBP experienced an increase in SBP after randomi-
zation in both treatment groups, although the in-
crease was smaller in the MRA group (10, 15–18). In
contrast, patients with higher SBP experienced a
decrease in SBP after randomization, although more
so with MRA treatment than with placebo. This likely
reflects the phenomenon of “regression to the mean.”
It is also of interest to compare the present findings
in patients with HFrEF with those with spi-
ronolactone in HF with preserved EF (HFpEF), where
patients often have a hypertensive background and
usually have a higher SBP than individuals with
HFrEF. In patients from North and South America
enrolled in the TOPCAT (Treatment of Preserved
Cardiac Function Heart Failure with an Aldosterone
Antagonist) trial, baseline SBP was 129 mm Hg. At
4 months, the change from baseline was þ0.94  SE
0.6) mm Hg in the placebo group and 2.75  SE 0.6,
giving a difference of 3.69  SE 0.86 mm Hg
(p < 0.001) (19).
In the present study, patients in the lowest SBP
group had a similar relative risk reduction in all out-
comes of interest with MRA treatment, as patients
with a higher SBP. This is relevant because many
physicians are concerned about prescribing drugs
with a hypotensive effect to heart failure patients
with low blood pressure, potentially depriving them
of the mortality benefit of these treatments (20).
Indeed, applying the overall relative risk reduction of
27% in all-cause mortality with MRA treatment, pa-
tients in the lowest SBP category would have the
greatest absolute mortality benefit because they had
the highest absolute mortality rate. Specifically,
treatment would lead to approximately 11 fewer
deaths per 100 patients treated with an MRA drug in
the SBP group of #105 mm Hg, compared with 6 fewer
deaths per 100 patients in the SBP group of
>135 mm Hg.
In keeping with the SBP change data reported
above, the rate of hypotension with MRA therapy,
assessed either by SBP measurement or adverse effect
reporting, was low. As expected, the highest rate of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Despite strong
guideline recommendations, registries show that many patients
with HFrEF are not treated with an MRA. One reason for with-
holding this treatment is low SBP. However, the present analysis
shows that MRAs have a small effect on SBP in patients with
HFrEF, are well tolerated even in patients with HFrEF with a low
SBP, and have a large absolute benefit in such individuals, as
patients with a low SBP are at high risk.
TRANSLATIONAL OUTLOOK: Contrary to that found in hy-
pertension, MRAs do not have a substantial SBP-lowering effect
in HFrEF. This appears to be generally true of all therapies that
are used as both antihypertensives and to treat HFrEF. Although
the reasons for this difference in the effect of treatment on SBP
in the 2 conditions are uncertain, it is important that health care
providers are aware of it so that life-saving treatments are not
withheld in HFrEF because of inappropriate concerns about
hypotension.
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197hypotension was reported in the lowest SBP cate-
gories, but this was the case with both placebo and
MRA treatment. The placebo-corrected difference in
rates of hypotension was similar across SBP cate-
gories, and the difference between randomized
treatments was not significant in any SBP category.
Moreover, the rates of severe renal dysfunction
(creatinine concentration of $3.0 mg/dl) and of
discontinuation of study drug were the same in the 2
treatment groups.
STUDY LIMITATIONS. First, it is retrospective, and
the analyses reported were not planned prospec-
tively. The measurement of blood pressure was not
standardized, which will have increased imprecision
around the values reported. Aldosterone levels,
which might have helped to understand the effects of
MRA treatment on SBP were not measured. The pro-
portions of patients treated with a beta-blocker at
baseline were significantly different in the 2 trials.
Rates of use of beta-blocker therapy in real world
registries are approximately 80%, but no evidence
was found that the blood pressure-lowering effects of
MRA were different in the 2 trials, where beta-blocker
use was different at baseline. The present results
would therefore be applicable to the wider population
where rates of beta-blocker use lie between these
2 extremes.
Finally, the effects of eplerenone, according to
baseline SBP at or above versus below the median
value (123 mm Hg), have previously been described in
EMPHASIS-HF, although only the primary composite
outcome was reported (21).
CONCLUSIONS
MRA treatment was found to have little effect on SBP
in patients with HFrEF, in contrast to the case in
hypertension. The beneficial effect of MRA therapyon clinical outcomes in patients with HFrEF was not
modified by baseline SBP. Because patients with
HFrEF with the lowest SBP had the highest event
rates, they had the greatest absolute benefit from
MRA therapy. Hypotension was infrequently caused
by MRA treatment, even in patients with a low base-
line SBP. MRA therapy was discontinued at a rate
similar to that of placebo overall and in patients with
the lowest baseline SBP. Low SBP is not a reason to
withhold MRA therapy in patients with HFrEF.
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